VeraBIND Tau test, a novel plasma assay for active tau pathology, identifies individuals with positive tau‐PET signal, regardless of amyloid status
Whereas pTau217 is more closely associated with amyloid than with tau-PET results, VeraBIND Tau is highly sensitive to (early) tau-PET positivity, indicating active tau aggregation, with or without amyloidosis. The mismatch between pTau217 and VeraBIND results provides a plasma indication of discordant A/T PET-status.
Authors
- Renaud Lhommel (ORCID: https://orcid.org/0000-0003-0668-6122)
- Adrian Ivanoiu
- Bernard Hanseeuw (ORCID: https://orcid.org/0000-0002-3102-6778)
- Lisa Quenon (ORCID: https://orcid.org/0000-0001-9139-2422)
- Joshua Soldo
- Emilien Boyer (ORCID: https://orcid.org/0009-0009-6222-4580)
- Jean‐Louis Bayart
- Khalid Iqbal
- Khairul Ansari
- Pascal Kienlen‐Campard
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- New York State Office for People With Developmental Disabilities (US)
- Gordon Center for Medical Imaging (US)
- Massachusetts General Hospital (US)
- Clinique Saint Pierre (BE)
- de Duve Institute (BE)
- UCLouvain Saint-Louis Brussels (BE)
- Athinoula A. Martinos Center for Biomedical Imaging (US)
- Grand Charleroi Hospital (BE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_105556
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00